Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain …
HJ Stemmler, M Schmitt, A Willems, H Bernhard… - Anti-cancer …, 2007 - journals.lww.com
Patients receiving trastuzumab for HER2-overexpressing metastatic breast cancer seem to
suffer from an increased risk of brain metastases, even in cases with responsive disease. To
evaluate whether trastuzumab is able to penetrate the blood–brain barrier, we measured
trastuzumab levels in the serum and in cerebrospinal fluid of metastatic breast cancer
patients with brain metastases receiving trastuzumab for HER2-overexpressing metastatic
breast cancer. In a pilot study, metastatic breast cancer patients with brain metastases and …
suffer from an increased risk of brain metastases, even in cases with responsive disease. To
evaluate whether trastuzumab is able to penetrate the blood–brain barrier, we measured
trastuzumab levels in the serum and in cerebrospinal fluid of metastatic breast cancer
patients with brain metastases receiving trastuzumab for HER2-overexpressing metastatic
breast cancer. In a pilot study, metastatic breast cancer patients with brain metastases and …